As Ozempic costs fall, demand for weight-loss drugs is set to surge
On the surface, lower GLP-1 prices should make these therapies easier to manage. But as Rae McMahan, SVP of Payer Solutions at Prescryptive, shared in her recent conversation with Employee Benefit News, the reality is more complex.
Recent price adjustments for GLP-1 medications like Ozempic and Wegovy are likely going to accelerate demand. And employers are likely to be on the front lines. Rae McMahan, SVP of Payer Solutions at Prescryptive, shared in her recent conversation with Employee Benefit News what employers need to be doing to get ready.
GLP-1s aren’t a typical pharmacy benefit. As demand grows, employers aren’t just managing higher utilization; they’re navigating how to ensure these therapies are used appropriately and sustainably.
Rae’s perspective is clear: success with GLP-1s isn’t just about expanding coverage. It’s about managing access intentionally.
That means:
- Ensuring the right patients are starting therapy
- Supporting adherence and clinical outcomes over time
- Creating cost structures that employers can sustain
GLP-1s are bringing long-standing challenges into sharper focus. And in response, new models are emerging that more directly connect employers to pharma companies in a direct access marketplace. GLP-1s may be driving demand today, but they’re also accelerating a broader redesign of how access to high-impact therapies is delivered.
See Rae’s full interview in Employee Benefit News. Ready to reexamine your GLP-1 approach? Reach out.